of chemotherapy with RTX and results the previously resulted HBV test results. Retrospective data analysis for screening was done after implementation of the software and its impact was assessed. Methods: We conducted retrospective chart review on
Search Results
QIM19-121: Improving Testing for Hepatitis B Before Treatment With Rituximab Through Automated Electronic Health Record Alert System: A Single Institutional Retrospective Review and Quality Improvement Project
Sowmya Boddhula, Satish Kumar Boddhula, Bishesh Shrestha, Kelly Morris, and Rosana Gnanajothy
EPR19-74: Risk of Cabozantinib-Associated Gastrointestinal and Hepatic Toxicities in Patients With Metastatic Solid Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Anita Sultan, Sriman Swarup, Francis Mogollon-Duffo, Ye Aung, Yin M. Myat, Myo H. Zaw, Rachana Yendala, Nicholas D’Cunha, and Kyaw Z. Thein
. These pathways are implicated in several tumor development and progression. We performed a systematic review and meta-analysis of randomized controlled trials (RCT) to determine the risk of gastrointestinal (GI) and hepatic toxicities among patients with
A Brief Review of Pharmacotherapies for Smoking Cessation
Cho Y. Lam, Jennifer A. Minnix, Jason D. Robinson, and Paul M. Cinciripini
nicotine patch: a randomized controlled trial . Addiction 2004 ; 99 : 634 – 640 . 25. Perkins K . Response to Dar and Frenk 2004, ``Do smokers self-administer pure nicotine? A Review of the evidence'' . Psychopharmacology Berl 2004 ; 175
The Economic Impact of Non-Melanoma Skin Cancer: A Review
Tejaswi Mudigonda, Daniel J. Pearce, Brad A. Yentzer, Phillip Williford, and Steven R. Feldman
settings and different physician groups involved, and evaluating results of recent studies comparing the cost of different treatment modalities with respect to procedure type, tumor size, and tumor location. Analysis and review of the current literature on
Small Cell Lung Cancer in Elderly Patients: A Review
Taofeek K. Owonikoko and Suresh Ramalingam
Vougiouka M . Cisplatin and platinum drugs at the molecular level [review] . Oncol Rep 2003 ; 10 : 1663 – 1682 . 18. Skarlos DV Samantas E Kosmidis P . Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in
Review of the Role of Opioids in Cancer Pain
Andrea M. Trescot
1. Boyle P . The globalisation of cancer . Lancet 2006 ; 368 : 629 – 630 . 2. van den Beuken-van Everdingen MH de Rijke JM Kessels AG . Prevalence of pain in patients with cancer: a systematic review of the past 40 years . Ann
Clinical Discussion and Review of the Management of Brain Metastases
Priscilla K. Brastianos, William T. Curry, and Kevin S. Oh
randomized trials address the roles of WBRT and SRS in patients with greater than 4 brain metastases. These conclusions are consistent with those of the evidence-based review 25 and guidelines 26 published by the American Society for Radiation Oncology
Imatinib-Induced Bone Edema: Case Report and Review of Literature
Lucas Vieira dos Santos, João Paulo Lima, Kathia Cristina Abdalla, Arinilda Campos Bragagnoli, Florinda Almeida Santos, Alexandre dos Anjos Jácome, and Fabiano Elias Porto
journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the post-test with a 66% minimum passing score and complete the evaluation at http://education.nccn.org/node/30367 ; and 4) view
A Review of VEGF/VEGFR-Targeted Therapeutics for Recurrent Glioblastoma
David A. Reardon, Scott Turner, Katherine B. Peters, Annick Desjardins, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon II, Lee W. Jones, John P. Kirkpatrick, Allan H. Friedman, James J. Vredenburgh, Darell D. Bigner, and Henry S. Friedman
studies attempting to more effectively exploit this therapeutic strategy. This article reviews the development, current status, and future challenges of VEGF-targeting therapeutics for patients with recurrent glioblastoma. Angiogenesis in Malignant
Management of Recurrent Small Cell Lung Cancer
Bryan J. Schneider
Small cell lung cancer remains one of the more frustrating malignancies for oncologists to treat. Although responses to initial platinum-based chemotherapy are high, most are not durable, and many patients are candidates for further palliative chemotherapy. Therapeutic options include reinduction or single-agent chemotherapy, depending on the duration of response to front-line treatment. Topotecan is the only approved agent for patients with relapsed disease. Several phase II studies have shown a modest benefit with other agents used today, although combination chemotherapy should be avoided because of increased toxicity. Palliative care should always be the focus, especially in patients with recurrent or chemorefractory small cell lung cancer and a poor performance status.
